Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Capital Expenditures: 2013-2025

Historic Capital Expenditures for KalVista Pharmaceuticals (KALV) over the last 13 years, with Apr 2025 value amounting to $495,000.

  • KalVista Pharmaceuticals' Capital Expenditures rose 118.69% to $234,000 in Q2 2025 from the same period last year, while for Apr 2025 it was $499,000, marking a year-over-year increase of 24.44%. This contributed to the annual value of $495,000 for FY2025, which is 23.44% up from last year.
  • As of FY2025, KalVista Pharmaceuticals' Capital Expenditures stood at $495,000, which was up 23.44% from $401,000 recorded in FY2024.
  • In the past 5 years, KalVista Pharmaceuticals' Capital Expenditures ranged from a high of $1.2 million in FY2023 and a low of $82,000 during FY2021.
  • Its 3-year average for Capital Expenditures is $697,333, with a median of $495,000 in 2025.
  • Per our database at Business Quant, KalVista Pharmaceuticals' Capital Expenditures surged by 1,035.37% in 2022 and then plummeted by 66.47% in 2024.
  • KalVista Pharmaceuticals' Capital Expenditures (Yearly) stood at $82,000 in 2021, then surged by 1,035.37% to $931,000 in 2022, then grew by 28.46% to $1.2 million in 2023, then tumbled by 66.47% to $401,000 in 2024, then rose by 23.44% to $495,000 in 2025.